AVBP - CIK 0001868279
The table below shows ArriVent BioPharma, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $37.62M | $32.17M | $27.72M | $61.29M | $20.09M | $21.78M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.49M |
| $6.15M |
| $5.90M |
| $5.48M |
| $4.14M |
| $3.92M |
| Operating income | -$46.11M | -$38.32M | -$33.62M | -$66.77M | -$24.23M | -$25.70M |
| Income tax | - | - | - | - | - | - |
| Net income | -$43.32M | -$34.98M | -$31.40M | -$64.39M | -$20.56M | -$21.87M |
| EPS (diluted) | -$0.96 | -$0.83 | -$0.90 | -$1.90 | -$0.61 | -$0.65 |